Handelsavisen
prelaunch
Companies Healthcare NXTMH.HE
NX
NXTMH.HE Nasdaq Helsinki Advanced Medical Equipment & Technology

Nexstim Oyj

€9,16
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
5,8 %
ROE
13,7 %
Net margin
5,2 %
Debt / equity
0,99
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

NXTMH.HE develops and sells advanced medical equipment and technology, primarily generating revenue through the sale of diagnostic and therapeutic devices.

Business. NXTMH.HE is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Nasdaq Helsinki exchange under the ticker NXTMH.HE.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target11,50

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
11,50
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
13,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NXTMH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NXTMH.HE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    NXTMH.HE is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Nasdaq Helsinki exchange under the ticker NXTMH.HE.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    NXTMH.HE has a debt-to-equity ratio of 0.99, indicating a balanced capital structure with moderate leverage. The company's liquidity is assessed as medium, with a current ratio of 1.27, suggesting it can cover its short-term obligations but with limited buffer. Free cash flow is negative at -57,860 EUR, which may indicate reinvestment in the business or operational inefficiencies.

    Profitability metrics show a return on equity of 13.71% and a return on assets of 4.35%, which are strong indicators of efficient use of equity and assets. The operating margin is 5.80%, and the net profit margin is 5.23%, both of which are in line with industry expectations for a company in the Advanced Medical Equipment & Technology sector.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to regional economic or regulatory risks.

    Outlook data indicates a projected growth in revenue for the current fiscal year, with a positive delta expected. However, the next fiscal year's growth is uncertain, with no significant changes in revenue expected. Historical revenue growth has been steady, with a total revenue of 10,968,810 EUR in the latest reporting period.

    Risk factors include a medium liquidity risk due to a current ratio of 1.27 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. No recent events or filings have been disclosed that would significantly impact the company's operations or financial position.

    Key takeaways
    • NXTMH.HE maintains a balanced capital structure with a debt-to-equity ratio of 0.99.
    • The company's profitability is strong, with a return on equity of 13.71%.
    • Revenue is concentrated in a single business segment, which may increase risk exposure.
    • Liquidity is assessed as medium, with a current ratio of 1.27.
    • Free cash flow is negative, indicating potential reinvestment or operational inefficiencies.
    • "margin_outlook_rationale": "Operating and net profit margins are stable, with no significant changes expected in the near term.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €9,16
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    €4.2M
    Net cash
    -€4.1M
    Current ratio
    1.3
    Debt / equity
    1.0
    ROA
    4.3%
    ROE
    13.7%
    Cash conversion
    291.0%
    CapEx / revenue
    -15.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,14
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,14
    Revenueno estimateno estimate13,0M EUR
    Operating incomeno estimateno estimate1,0M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target€11,50 · Median €11,50
    Low €11,50High €11,50
    Operating income · consensus1,0M EUR
    EPS surprise
    −57,1 %
    reported vs consensus · miss
    Revenue surprise
    −15,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€11,50
    Mean€11,50
    Median€11,50
    High€11,50
    Spot€9,16
    +25.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin5,8 %Above median
    Net Margin5,2 %Above median
    ROE13,7 %Above P75
    Capex / Rev-15,5 %Bottom quartile
    D/E0,99Bottom quartile
    Cash Conv2,91Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • NXTMH.HE Market data — financials · 2026-05-28
    • Nexstim Oyj Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NXTMH.HECanonical
    Nasdaq Helsinki · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage